Recently, the Xeligekimab Injection (trade name: 金立希/Jin Li Xi) of Chongqing Genrix Biopharmaceutical Co., Ltd. is approved by China NMPA. It is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis through systematic treatment or phototherapy.

The Xeligekimab Injection is a recombinant fully human IgG4 subtype anti-interleukin-17A (IL-17A) monoclonal antibody that inhibits the onset and progression of inflammation by specifically binding to IL-17A protein in serum and blocking the binding of IL-17A to IL-17RA (IL-17A receptor).

The marketing of this product provides a new treatment option for adult patients with plaque psoriasis.